new version V2017

percutaneous coronary intervention
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

anti inflammatory drugs

pexelizumab
COMMA, 2003pexelizumabplaceboNegative
COMPLY, 2003pexelizumabplaceboNegative
APEX-AMI, 2007pexelizumabplacebo Low risk of bias NegativeNCT00091637

antiplatelets drug

bivalirudin
BRAVE-4 ongoing Prasugrel and BivalirudinClopidogrel and Heparin - NCT00976092
cangrelor
CHAMPION-PCI, 2009cangrelor up frontclopidogrel up front Low risk of bias NegativeNCT00305162
CHAMPION-PLATFORM, 2009cangrelor up frontdelayed clopidogrelNegativeNCT00385138
CHAMPION PHOENIX, 2013cangrelorclopidogrel Low risk of bias SuggestingNCT01156571
elinogrel
INNOVATE PCIelinogrelclopidogrel - NCT00751231
enoxaparin
STREAM ongoing enoxaparinunfractionated heparin - NCT00882635
prasugrel
TRITOM TIMI 38 (PCI subgroup), 2009prasugrelclopidogrel -
TRIGGER-PCI ongoing prasugrelClopidogrel - NCT00910299

antithrombotics

aspirin
Taylor (Perth), 1991aspirinplaceboNegative
M-HEART II (aspirin), 1995aspirinplaceboNegative
bivalirudin
ARMYDA BIVALVEbivalirudinUFH -
BAT (Bittl), 1995bivalirudinUFH Low risk of bias Suggesting
Kleiman, 2002bivalirudin + eptifibatideheparin + GP2b3a inhibitors Exploratory -
REPLACE-2, 2003bivalirudinheparin + GP2b3a inhibitors -
REPLACE-1, 2004bivalirudinUFH Exploratory Negative
ACUITY (Stone) (bivalirudin alone), 2006bivalirudinheparin + GP2b3a inhibitors Risk of bias - NCT00093158
HORIZONS-AMI (Stone), 2008bivalirudinheparin + GP2b3a inhibitors Risk of bias SuggestingNCT00433966
ISAR-REACT 3, 2008bivalirudinUFH Low risk of bias - NCT00262054
NAPLES (Tavano), 2009bivalirudinUFH plus tirofiban Risk of bias Suggesting
dalteparin
Natarajan (without antiGp2b3a), 2003dalteparinUFH -
Natarajan (+ antiGp2b3a), 2003dalteparinUFH + anti Gp2b3a -
dipyridamol
Schwartz (Toronto), 1988aspirin + dipyridamolplaceboSuggesting
Mayo-PTCA, 1989aspirin + dipyridamolplaceboNegative
Nye (Dunedin), 1990aspirin + dipyridamolplaceboNegative
White (aspirin+dipiridamol), 1991aspirin + dipyridamolplaceboNegative
enoxaparin
Rabah, 1999enoxaparinUFH Exploratory Negative
Dudek, 2000enoxaparinUFHNegative
Dudek b (enox alone), 2000enoxaparinUFH -
Galeote, 2001enoxaparinUFHNegative
Drozd, 2001enoxaparinUFHNegative
Dubek b (+abciximal), 2001enoxaparin+abciximabUFH -
CRUISE, 2003enoxaparinUFH Exploratory Negative
STEEPLE, 2006enoxaparinUFH Risk of bias - NCT00077844
ATOLL, 2010enoxaparinUFH Risk of bias -
fondaparinux
SWITCH III ongoing fondaparinuxunfractionated heparin or bivalirudin - NCT00464087
prasugrel
JUMBO-TIMI 26, 2005prasugrelclopidogrel Exploratory Negative
reviparin
REDUCE, 1996reviparinUFH Low risk of bias Suggesting
sulotroban
M-HEART II (sulotroban), 1995sulotrobanplacebo -
ticlopidine
TACT, 1990ticlopidineplaceboNegative
White (ticlopidine), 1991ticlopidineplacebo -

restenosis prevention

amlodipine
Jorgensen (NICOLE), 2001amlodipineplaceboSuggesting
diltiazem
Corcos, 1985diltiazemcontrolNegative
O’Keefe, 1991diltiazemplaceboNegative
Unverdorben, 1996diltiazemplaceboSuggesting
nifedipine
Whitworth, 1986nifedipineplaceboNegative
nisoldipine
Dens (CAPARES), 2000nisoldipineplaceboSuggesting
rosiglitazone
PROVIDENCE ongoing rosiglitazoneplacebo Exploratory - NCT00116792
verapamil
Hoberg, 1994verapamilplaceboNegative

statins

atorvastatin
GAIN, 2001atorvastatinusual careNegative
ARMYDA, 2004atorvastatinplaceboSuggesting
NAPLES II (Briguori), 2009atorvastatincontrolSuggesting
ARMYDA-RECAPTURE, 2009atorvastatin reloadplacebo Low risk of bias Suggesting
ESTATE ongoing Atorvastatincontrol - NCT00979940
fluvastatin
FLARE, 1999fluvastatinplaceboNegative
LIPS, 2002fluvastatinplaceboNegative
pravastatin
PREDICT, 1997pravastatinplaceboNegative



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons